• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    2/13/24 5:00:42 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 2)*

     

    Vir Biotechnology, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    92764N102

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 1 of 7

     

    1

    Names of Reporting Persons

     

    SVF Endurance (Cayman) Limited

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    Not Applicable
    11 Percent of Class Represented by Amount in Row 9

    12.4%
    12 Type of Reporting Person

    CO

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 2 of 7

     

    1

    Names of Reporting Persons

     

    SoftBank Vision Fund (AIV M1) L.P.

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares

    Beneficially Owned by Each Reporting Person With

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    12.4%

    12

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 3 of 7

     

    1

    Names of Reporting Persons

     

    SB Investment Advisers (UK) Limited

    2 Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,684,041

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,684,041

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,684,041

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    12.4%

    12

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 4 of 7

     

    ITEM 1. (a) Name of Issuer:

     

    Vir Biotechnology, Inc. (the “Issuer”).

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    1800 Owens Street, Suite 900, San Francisco, CA 94158

     

    ITEM 2. (a) Name of Person Filing:

     

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

    SVF Endurance (Cayman) Limited

    SoftBank Vision Fund (AIV M1) L.P. (“SVF”)

    SB Investment Advisers (UK) Limited (“SBIA UK”)

     

      (b) Address or Principal Business Office:

     

    The principal business address of SVF Endurance (Cayman) Limited is c/o Walkers Corporate Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The principal business address of SVF is 251 Little Falls Drive Wilmington, DE 19808. The principal business address of SBIA UK is 69 Grosvenor Street, London, W1K 3JP, United Kingdom.

     

      (c) Citizenship of each Reporting Person is:

     

    SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands. SVF is organized under the laws of the State of Delaware. SBIA UK is organized under the laws of England and Wales.

     

      (d) Title of Class of Securities:

     

    Common stock, par value $0.0001 per share (“Common Stock”).

     

      (e) CUSIP Number:

     

    92764N102

     

    ITEM 3.

     

    Not applicable.

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 5 of 7

     

    ITEM 4. Ownership.

     

    (a-c)

     

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 134,521,285 shares of Common Stock outstanding as of October 27, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2023.

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class:

       Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

    Sole power to dispose or to direct the disposition

    of:

      

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     
    SVF Endurance (Cayman) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 
    SoftBank Vision Fund (AIV M1) L.P.   16,684,041    12.4%   0    16,684,041    0    16,684,041 
    SB Investment Advisers (UK) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 

     

    SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF is the sole owner of SVF Endurance (Cayman) Limited.

     

    SBIA UK has been appointed as alternative investment fund manager (“AIFM”) of SVF. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SVF’s investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

     

    ITEM 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    ITEM 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    ITEM 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    ITEM 10. Certification.

     

    Not applicable.

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 6 of 7

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

      SVF Endurance (Cayman) Limited
       
      By: /s/ Karen Ellerbe
      Name: Karen Ellerbe
      Title: Director
       
      SoftBank Vision Fund (AIV M1) L.P.
       
      By: SB Investment Advisers (UK) Limited, its manager
       
      By: /s/ Amanda Sanchez-Barry
      Name: Amanda Sanchez-Barry
      Title: General Counsel
       
      SB Investment Advisers (UK) Limited
       
      By: /s/ Amanda Sanchez-Barry
      Name: Amanda Sanchez-Barry
      Title: General Counsel

     

     

     

     

    CUSIP No. 92764N102 Schedule 13G Page 7 of 7

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
    99   Joint Filing Agreement (previously filed).

     

     

     

    Get the next $VIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    2/24/2026$19.00Outperform → Strong Buy
    Raymond James
    9/3/2025$12.00Outperform
    Evercore ISI
    8/27/2025$14.00Neutral → Buy
    BofA Securities
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $VIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

    - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48 subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for poster tour by EASL Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chro

    5/18/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m

    5/14/26 10:55:00 AM ET
    $GTBP
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

    - Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate cancer - Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the Study of the Liver (EASL) Congress - Strong financial position with $809.3 million in cash and investments as of March 31, 2026, excluding $315 million combined Astellas upfront payment1 and equity investment to be received in the second quarter of 2026 - Conference call scheduled for May

    5/6/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vir Biotechnology upgraded by Raymond James with a new price target

    Raymond James upgraded Vir Biotechnology from Outperform to Strong Buy and set a new price target of $19.00

    2/24/26 7:40:37 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI initiated coverage on Vir Biotechnology with a new price target

    Evercore ISI initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $12.00

    9/3/25 8:41:05 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology upgraded by BofA Securities with a new price target

    BofA Securities upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $14.00

    8/27/25 8:18:54 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    6/2/26 5:35:21 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    6/2/26 5:31:54 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    5/28/26 7:25:45 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    SEC Filings

    View All

    Vir Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

    5/28/26 9:01:18 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

    5/6/26 4:11:32 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Vir Biotechnology Inc.

    DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)

    4/16/26 8:49:02 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Financials

    Live finance-specific insights

    View All

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m

    5/14/26 10:55:00 AM ET
    $GTBP
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

    4/23/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity – Strong financial position with $781.6 million in cash and investments as of December 31, 2025 – Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. "This is a seminal moment for Vir Biotechnology

    2/23/26 5:14:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Leadership Updates

    Live Leadership Updates

    View All

    Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

    – ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 – ECLIPSE registrational program on target, with ECLIPSE 2 and 3 enrolling well and in line with the Company's expectations – Swift recruitment underscores high unmet medical need for effective and convenient chronic hepatitis delta treatment Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE 1 is one of three t

    11/3/25 8:00:00 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

    – Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation

    9/10/24 8:05:00 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

    4/1/24 8:00:00 AM ET
    $LCTX
    $SYBX
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $VIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vir Biotechnology Inc.

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    10/18/24 12:29:43 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    2/13/24 5:17:30 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    2/13/24 5:00:42 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care